Abstract 179P
Background
Whether postoperative adjuvant transarterial chemoembolization (PA-TACE) can prolong overall survival (OS) in patients with resected hepatocellular carcinoma (HCC) remains confusion. We aimed to assess and compare the efficacy of PA-TACE and surgery alone in patients with resected HCC.
Methods
Data from patients who underwent surgery were selected and collected for retrospectively analysis. A propensity-score 1:1 matching analysis was performed. The overall survival was analyzed by the Kaplan-Meier method, and survival outcomes for patients who underwent PA-TACE were compared with those who underwent surgery alone.
Results
A total 286 patients (PA-TACE vs surgery alone, 143:143) were identified and selected after a propensity-score 1:1 matching analysis. No significant difference was observed in each variable in the matched data. And, all Kaplan-Meier curves for overall survival between PA-TACE and surgery alone group showed significance before and after propensity score matching (P = 0.0065 and P < 0.001, respectively). Subgroup analysis showed patients with low BCLC stage and low albumin-bilirubin grade had a better overall survival in the PA-TACE group.
Conclusions
Compared to surgery alone, PA-TACE could prolonger overall survival in patients with resected HCC, especially for who with low BCLC stage and/or low albumin-bilirubin grade.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiujun Cai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract